BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics Ginkgo Bioworks Acquires Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs Modulus Therapeutics is a cell engineering company focused on the design ...

3 Tips for Sizing Your Penny Stocks Positions in 2024Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing. This strategy ensures that investors can capitalize on opportunities without exposing themselves to undue risk. Three key tips can guide traders in optimizing their investment approach to penny stocks in 2024.[Read More] ...

Ginkgo Bioworks (DNA 1.89%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments.But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.Why this comp ...

LEIDEN, Netherlands , March 13, 2024 /PRNewswire/ -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for ...

The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of o ...

Could Ginkgo Bioworks Holdings (DNA -15.13%) one day be part of the healthcare sector's version of the "Magnificent Seven" group of high-performing stocks? It's more likely than you think. The Boston-based biofoundry has large aspirations to disrupt the way new drugs are developed -- and there's reason to believe that over time it could succeed in a big way. Consider the following.The argument for "magnificent" statusPerhaps the most illustrious of the current Magnificent Seven stocks (which all focus on te ...

Shares of Ginkgo Bioworks (DNA -10.53%) were sinking 9.5% lower as of 11:34 a.m. ET on Friday. The sell-off came after the biotechnology company announced its fourth-quarter and full-year 2023 results following the market close on Thursday.Ginkgo reported Q4 revenue of $34.8 million, down 65% year over year. This result was well below the Wall Street consensus estimate of $42.5 million.The company posted a fourth-quarter net loss of $211.7 million, or $0.11 per share. The average analyst estimate was for a ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2023 Earnings Conference Call February 29, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly – Co-Founder and Chief Executive Officer Mark Dmytruk – Chief Financial Officer Conference Call Participants Steve Mah – Cowen Tejas Savant – Morgan Stanley Mark Massaro – BTIG Matt Sykes – Goldman Sachs Derik de Bruin – Bank of America Matt Larew – William Blair Michael Freeman – Raymond James Megan LeDuc Good evening, I’m Megan Le ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Ginkgo Bioworks Holdings, Inc., which ...

$251 million of Total revenue in 2023 $139 million in Cell Engineering services revenue, representing 31% growth over 2022 78 new Cell Programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma Year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency BOSTON, Feb. 29, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which ...